The flu forces a reformulation of the vaccine and delays its production across Europe

The simultaneous update of the three strains in the flu vaccine for the 2026-2027 season has tested European manufacturers' production capacity, causing delays in supply across various countries. Jaime Jesús Pérez Martín from the Spanish Vaccinology Association highlights that the change in strains has particularly impacted egg-based vaccines, which have faced growth issues. Viatris confirmed that its external manufacturer, Abbott, encountered difficulties due to the exceptional update of the strains recommended by the WHO, compounded by delays in critical material availability and operational challenges. Despite these setbacks, health authorities have adapted vaccination campaigns, prioritizing vulnerable groups. Experts believe the situation is manageable, with no significant health consequences expected, as flu circulation typically increases in November.